FDA conditionally approves drug for canine neuropathic painMay 13, 2026Liavium-CA1 is indicated for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. The drug, with the active ingredient pregabalin, reduces the release of neurotransmitters that send pain signals in the spinal cord.
SPONSORED CONTENTUncompromising renal + sensitivities care.Managing pain from canine OA doesn’t have to be complicated. Discover an approach that doesn’t just treat pain, but addresses inflammation, too. + Learn More
